Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71–96.
•• US Preventive Services Task Force: Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:627–637. This is a summary of the USPSTF guidelines.
•• Levin B, Lieberman DA, McFarland B, et al.: Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008, 58:130–160. This is a summary of the ACS-MSTF-ACR guidelines.
•• Rex DK, Johnson DA, Anderson JC, et al.: American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009, 104:739–750. This is a summary of the ACG guidelines.
Mandel JS, Bond JH, Church TR, et al.: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328:1365–1371.
Hardcastle JD, Chamberlain JO, Robinson MH, et al.: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348:1472–1477.
Kronborg O, Fenger C, Olsen J, et al.: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348:1467–1471.
Greenberg PD, Bertario L, Gnauck R, et al.: A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000, 95:1331–1338.
Allison JE, Sakoda LC, Levin TR, et al.: Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007, 99:1462–1470.
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al.: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004, 351:2704–2714.
• van Rossum LG, van Rijn AF, Laheij RJ, et al.: Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008, 135:82–90. This study comparing gFOBT with FIT demonstrated greater participation and more detection of advanced adenomas and cancer with FIT testing.
Rozen P, Waked A, Vilkin A, et al.: Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006, 12:MT27–MT32.
Morikawa T, Kato J, Yamaji Y, et al.: A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422–428.
• Dancourt V, Lejeune C, Lepage C, et al.: Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008, 44:2254–2258. This study compared 3-day gFOBT with 2-day FIT. The results demonstrated superior performance of FIT in detecting advanced adenomas and cancers but at the cost of more false-positive tests.
• Rozen P, Levi Z, Hazazi R, et al.: Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009, 29:450–457. This study from Israel compared the performance of 3-day gFOBT with that of FIT in patients scheduled to undergo colonoscopy. The specificity of 1-day FIT was superior to that of gFOBT, with no difference in sensitivity.
•• Hundt S, Haug U, Brenner H: Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009, 150:162–169. This study from Germany compared six FITs and gFOBTs in detecting advanced neoplasia. It demonstrated that test performance is variable among all tests.
Grazzini G, Visioli CB, Zorzi M, et al.: Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening? Br J Cancer 2009, 100:259–265.
• Ahlquist DA, Sargent DJ, Loprinzi CL, et al.: Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008, 149:441–450, W481. This study evaluated the performance of old and new versions of the fecal DNA stool test. Although the authors highlighted the limitations of this test in detecting advanced neoplasia, they noted improved performance in the second version of the test.
Gross CP, Andersen MS, Krumholz HM, et al.: Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA 2006, 296:2815–2822.
Imperiale TF, Wagner DR, Lin CY, et al.: Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000, 343:169–174.
Lieberman DA, Weiss DG, Bond JH, et al.: Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000, 343:162–168.
Schoenfeld P, Cash B, Flood A, et al.: Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005, 352:2061–2068.
• Lieberman DA, Holub JL, Moravec MD, et al.: Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients. JAMA 2008, 300:1417–1422. This study of patients undergoing screening colonoscopy demonstrated a higher likelihood of proximal and advanced lesions in black subjects.
Levin TR, Palitz A, Grossman S, et al.: Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy. JAMA 1999, 281:1611–1617.
Newcomb PA, Norfleet RG, Storer BE, et al.: Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992, 84:1572–1575.
Selby JV, Friedman GD, Quesenberry CP Jr, et al.: A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992, 326:653–657.
Thiis-Evensen E, Hoff GS, Sauar J, et al.: Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999, 34:414–420.
•Hoff G, Grotmol T, Skovlund E, et al.: Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009, 338:b1846. This recent randomized controlled trial demonstrated that after 7 years of follow-up, there was no measurable difference in CRC mortality with flexible sigmoidoscopy compared with controls.
Mandel JS, Church TR, Bond JH, et al.: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000, 343:1603–1607.
Winawer SJ, Zauber AG, Ho MN, et al.: Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993, 329:1977–1981.
Citarda F, Tomaselli G, Capocaccia R, et al.: Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001, 48:812–815.
Muller AD, Sonnenberg A: Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995, 123:904–910.
•• Baxter NN, Goldwasser MA, Paszat LF, et al.: Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009, 150:1–8. This case-control study from Ontario demonstrated a protective effect of colonoscopy against left-sided CRC (odds ratio, 0.33) but not right-sided CRC. It suggested that colonoscopy may not be effective in the proximal colon.
Singh H, Turner D, Xue L, et al.: Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA 2006, 295:2366–2373.
Pickhardt PJ: Incidence of colonic perforation at CT colonography: review of existing data and implications for screening of asymptomatic adults. Radiology 2006, 239:313–316.
Pickhardt PJ, Choi JR, Hwang I, et al.: Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003, 349:2191–2200.
Cotton PB, Durkalski VL, Pineau BC, et al.: Computed tomographic colonography (virtual colonoscopy): a multicenter comparison with standard colonoscopy for detection of colorectal neoplasia. JAMA 2004, 291:1713–1719.
•• Johnson CD, Chen MH, Toledano AY, et al.: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 2008, 359:1207–1217. This recent study evaluated the performance of CTC in detecting large adenomas and cancer. The results showed a sensitivity of 84% for large adenomas and cancers.
• Soetikno RM, Kaltenbach T, Rouse RV, et al.: Prevalence of nonpolypoid (flat and depressed) colorectal neoplasms in asymptomatic and symptomatic adults. JAMA 2008, 299:1027–1035. This study demonstrated that nonpolypoid neoplasms of the colon may be more prevalent in the Western population than previously thought and may contain advanced histology more frequently.
Gluecker TM, Johnson CD, Wilson LA, et al.: Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population. Gastroenterology 2003, 124:911–916.
Hara AK, Johnson CD, MacCarty RL, et al.: Incidental extracolonic findings at CT colonography. Radiology 2000, 215:353–357.
Yee J, Kumar NN, Godara S, et al.: Extracolonic abnormalities discovered incidentally at CT colonography in a male population. Radiology 2005, 236:519–526.
Pickhardt PJ, Taylor AJ: Extracolonic findings identified in asymptomatic adults at screening CT colonography. AJR Am J Roentgenol 2006, 186:718–728.
• Lieberman D, Moravec M, Holub J, et al.: Polyp size and advanced histology in patients undergoing colonoscopy screening: implications for CT colonography. Gastroenterology 2008, 135:1100–1105. This study reviewing the prevalence of advanced histology in polyps of various sizes found advanced neoplasia in 6.6% of polyps 6 to 9 mm in diameter. This finding has implications for the risk of missed advanced neoplasia in patients undergoing CTC who choose to follow up polyps of this size with continued CT surveillance.
Adams KF, Leitzmann MF, Albanes D, et al.: Body mass and colorectal cancer risk in the NIH-AARP cohort. Am J Epidemiol 2007, 166:36–45.
Driver JA, Gaziano JM, Gelber RP, et al.: Development of a risk score for colorectal cancer in men. Am J Med 2007, 120:257–263.
Giovannucci E: An updated review of the epidem+iological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001, 10:725–731.